Holen Sie sich die Stockscreener-App
1.15
0.88%
0.01
Vorhandelsmarkt:
1.17
0.02
+1.74%
Schlusskurs vom Vortag:
$1.14
Offen:
$1.12
24-Stunden-Volumen:
7.02M
Relative Volume:
2.73
Marktkapitalisierung:
$448.92M
Einnahmen:
$86.26M
Nettoeinkommen (Verlust:
$-50.08M
KGV:
-4.6958
EPS:
-0.2449
Netto-Cashflow:
$-94.48M
1W Leistung:
+11.65%
1M Leistung:
+29.64%
6M Leistung:
-23.33%
1J Leistung:
+8.49%
1-Tages-Spanne:
$1.095
$1.185
1-Wochen-Bereich:
$1.02
$1.185
52-Wochen-Spanne:
$0.8701
$1.72
Standard Biotools Inc Stock (LAB) Company Profile
Firmenname
Standard Biotools Inc
Sektor
Branche
Telefon
(650) 266-6000
Adresse
50 MILK STREET, BOSTON
Compare LAB vs ABT, SYK, MDT, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LAB
Standard Biotools Inc
|
1.15 | 445.02M | 86.26M | -50.08M | -94.48M | -0.2449 |
ABT
Abbott Laboratories
|
85.60 | 150.32B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
305.09 | 117.93B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
73.81 | 97.02B | 35.48B | 4.64B | 5.41B | 3.582 |
BSX
Boston Scientific Corp
|
48.31 | 72.99B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.47 | 49.50B | 6.30B | 1.07B | 1.09B | 1.8406 |
Standard Biotools Inc Stock (LAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-08-13 | Herabstufung | TD Cowen | Buy → Hold |
| 2025-02-27 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2024-04-16 | Eingeleitet | TD Cowen | Buy |
| 2024-04-04 | Eingeleitet | Jefferies | Buy |
| 2023-07-12 | Eingeleitet | KeyBanc Capital Markets | Overweight |
Standard Biotools Inc Aktie (LAB) Neueste Nachrichten
Standard BioTools Adopts New Executive Severance Protection Plans - TipRanks
Standard BioToolsapproves 2026 change of control and severance plan on May 21, 2026 - marketscreener.com
Standard BiotoolsApproves 2026 Change Of Control And Severance Plan On May 21, 2026 - TradingView
Standard BioTools CFO Alex Kim and CBO Sean Mackay enter 2026 Severance Plan; CEO Michael Egholm joins 2023 Plan - TradingView
Standard BioTools (LAB) sets new executive and CEO change-of-control severance terms - Stock Titan
Standard Biotools Inc Live Share Prices and Trades. LAB.US Live Streaming Share Prices. - London South East
Standard BioTools shares hold over $1 as Nasdaq deadline nears - Bez Kabli
Standard BioTools (LAB) Hovers Near Support After Modest DeclineBreakout Confirmation - thelegaladvocate.com
Standard BioTools (LAB) Nears Support After Slight Decline Amid Cautious TradingValue Stock Ideas - thelegaladvocate.com
STANDARD BIOTOOLS (LAB) CFO has 18,871 shares withheld for RSU taxes - Stock Titan
Standard Biotools (LAB) SVP has 25,729 shares withheld for taxes - Stock Titan
STANDARD BIOTOOLS (LAB) CEO has shares withheld to cover RSU tax obligations - Stock Titan
Standard BioTools Q1 2026 Earnings: Massive EPS Beat Fails to Lift Shares Amid Revenue UncertaintyProfit Announcement - Newser
DKSH : and Standard BioTools Announce Distribution Partnership to Expand Spatial Biology and Proteomics Solutions in Australia and New Zealand - marketscreener.com
Standard BioTools (LAB) Q1 2026 Earnings: $0.33 EPS Surges Past $-0.06 EstimatesStock Idea Hub - Newser
Standard BioTools (LAB) Q1 2026 Earnings Surprise: EPS $0.33, Up SignificantCrowd Consensus Signals - Newser
SomaLogic stock (US82489T1043): merger with Standard BioTools reshapes proteomics player - AD HOC NEWS
SomaLogic Inc stock (US82489T1043): Illumina merger closes and reshapes proteomics story - AD HOC NEWS
MAK Capital (NASDAQ: LAB) reports 6.7% stake in Standard BioTools - Stock Titan
Viking Global (LAB) holds 58.65M shares (~15%) of Standard BioTools - Stock Titan
Should You Sell Standard BioTools (LAB) After -1.52% Drop? 2026-05-15Collaborative Trading Signals - Newser
Standard BioTools (LAB) Q1 2026 Earnings: Why the Beat MattersBinary Event - newser.com
SomaLogic stock (US82489T1043): Completed $350M sale to Illumina - AD HOC NEWS
MSN Money - MSN
Standard BioTools (LAB) reports Q1 loss, tops revenue estimates - MSN
Standard BioTools Inc. (LAB) Stock Analysis: A 55% Potential Upside Beckons Investors - DirectorsTalk Interviews
Standard Biotools Faces Nasdaq Delisting Risk After Prolonged Sub-$1 Share Price - TipRanks
Number of shareholders of Standard BioTools Inc. – NASDAQ:LAB - TradingView
Standard BioTools (NASDAQ: LAB) posts Q1 2026 profit on SomaScan sale windfall - Stock Titan
Molecular Instruments and Standard BioTools Announce Collaboration to Bring Amplified Multi-Omic Readouts to Imaging Mass Cytometry - MSN
LAB Financials: Income Statement, Balance Sheet & Cash Flow | STANDARD BIOTOOLS INC - Stock Titan
Standard BioTools (LAB) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Standard BioTools: Q1 Earnings Snapshot - marketscreener.com
Standard BioTools Highlights Improved Q1 2026 Results, Outlook - TipRanks
Standard BioTools 1Q Loss $14.6M >LAB - Moomoo
Standard BioTools 1Q Rev $21.1M >LAB - Moomoo
Standard BioTools ends quarter with $524M as loss shrinks 54% - Stock Titan
Standard BioTools (LAB) Q1 2026 results show big cash boost and EBITDA gains - Stock Titan
Standard BioTools Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Standard BioTools Reports First Quarter 2026 Financial Results - ChartMill
Standard BioTools to Announce First Quarter 2026 Financial Results on May 5, 2026 - Investing News Network
Finanzdaten der Standard Biotools Inc-Aktie (LAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.59%
1.94%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):